MedTrace Logo

Cell-free DNA Quantification for Predictive Marker of Palliative Chemotherapy

NCT05227950 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-02-08

No results posted yet for this study

Summary

This study is design to address, as follows:

1. correlation between fluorescence-based CFD measurements and tumor burden (primary tumor size, number of metastatic sites)
2. fluorescence-based CFD measurements and changes are related to tumor response. Based on the results of this study, the role of fluorescence-based CFD as a predictive biomarker for palliative chemotherapy is to be confirmed.

Conditions

  • Cell-Free Nucleic Acids
  • Biomarkers
  • Fluorescence
  • Palliative Chemotherapy

Sponsors & Collaborators

  • Pusan National University Yangsan Hospital

    lead OTHER

Principal Investigators

  • Kwonoh Park, MD, phD · Medical Oncology and Hematology, Department of Internal medicine, Pusan National University Yangsan Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05227950 on ClinicalTrials.gov